SCHEMBL7124423

SCHEMBL7124423

CCCCCCCCCCCCCCCCNc1cc(OCCC)nc(N)[n+]1[O-]

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM2 P50570 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 1/20 0.33
ALDH1A1 P00352 1/20 0.33
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33
POLB P06746 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
KMT2A Q03164 1/20 0.33
TLR8 Q9NR97 7/20 0.33
NOS1 P29475 1/20 0.32
GPR84 Q9NQS5 1/20 0.32
CDK1 P06493 1/20 0.32
CCNB1 P14635 1/20 0.32
TLR7 Q9NYK1 2/20 0.31
SMPD1 P17405 1/20 0.31
BCHE P06276 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125650 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7117880 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7115946 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7125112 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7128032 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7121610 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7122685 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7117869 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7121624 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA
SCHEMBL7124374 1.00 DNM2 (0.33) DNM2L3MBTL1MEN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6653317-B2 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss SOCIETE L'OREAL S.A. (FR) 2003-11-25 US claimed
US-20030130294-A1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss MAHE YANN (FR) 2003-07-10 US claimed
US-6455054-B2 THERAPY FOR SKIN DISORDERS SOCIETE L'OREAL S.A. (FR) 2002-09-24 US claimed
US-20010051139-A1 TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS SOCIETE L'OREAL S.A. (FR) 2001-12-13 US claimed
US-20010044444-A1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss MAHE YANN (FR) 2001-11-22 US claimed
US-6291468-B1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss SOCIETE L'OREAL S.A. (FR) 2001-09-18 US claimed
US-6653317-B2 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss SOCIETE L'OREAL S.A. (FR) 2003-11-25 US disclosed
US-20030130294-A1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss MAHE YANN (FR) 2003-07-10 US disclosed
US-6511659-B2 Treatment of alopecia, cosmetics SOCIETE L'OREAL S.A. (FR) 2003-01-28 US disclosed
US-6455054-B2 THERAPY FOR SKIN DISORDERS SOCIETE L'OREAL S.A. (FR) 2002-09-24 US disclosed
US-20010051139-A1 TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS SOCIETE L'OREAL S.A. (FR) 2001-12-13 US disclosed
US-20010044444-A1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss MAHE YANN (FR) 2001-11-22 US disclosed
US-6291468-B1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss SOCIETE L'OREAL S.A. (FR) 2001-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010051139-A1 TREATING SKIN AFFLICTIONS/CONDITIONS WITH 2-AMINO-4-ALKYLAMINOPYRIMIDINE 3-OXIDE COMPOUNDS TPMT, IL33, PTGS2 DNM2 4229/4885L3MBTL1 1287/4885MEN1 4519/4885
US-20030130294-A1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss TK2, TYR, MTR DNM2 3975/4885L3MBTL1 2325/4885MEN1 4382/4885
US-20010044444-A1 Pyrimidine 3-oxide compounds for inducing/stimulating hair growth and/or retarding hair loss TK2, TYR, MTR DNM2 3947/4885L3MBTL1 2387/4885MEN1 4366/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.